October 31, 2023 11:33 AM EDT

FDA lifts clinical hold on Mersana’s STING agonist, PhI starting dose lowered after patient death

Ayisha Sharma

News Reporter

The FDA has lifted the full clinical hold on Mersana Therapeutics’ STING-targeted antibody-drug conjugate on the back of the company making Phase I study dosing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA lifts clinical hold on Mersana’s STING agonist, PhI starting dose lowered after patient death

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Secretive Treeline Biosciences discloses $421M financing in filing

FDA approves AbbVie's 24-hour Parkinson's infusion therapy after two CRLs

House’s prominent China critic Jim McGovern leads opposition to Biosecure Act: ‘I would prefer to go back to the ...

BenevolentAI CEO is out after less than a year on the job

Sage shakes up senior management, slashes pipeline, sheds 33% of staff

Join the GenScript Biotech Global Forum: Unlocking Innovations in Cell and Gene Therapies

FDA lifts clin­i­cal hold on Mer­sana’s STING ag­o­nist, PhI start­ing dose low­ered af­ter pa­tient death

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

FDA lifts clinical hold on Mersana’s STING agonist, PhI starting dose lowered after patient death